A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma

Background: Approximately 50% of melanomas harbor BRAF mutations. Treatment with BRAF +/− MEK inhibition is associated with favorable changes in the tumor microenvironment thus providing the rationale for combining targeted agents with immunotherapy. Methods: Patients with unresectable Stage III or...

Full description

Bibliographic Details
Main Authors: Meghan J. Mooradian, Alexandre Reuben, Peter A. Prieto, Mehlika Hazar-Rethinam, Dennie T. Frederick, Brandon Nadres, Adriano Piris, Vikram Juneja, Zachary A. Cooper, Arlene H. Sharpe, Ryan B. Corcoran, Keith T. Flaherty, Donald P. Lawrence, Jennifer A. Wargo, Ryan J. Sullivan
Format: Article
Language:English
Published: Taylor & Francis Group 2018-05-01
Series:OncoImmunology
Subjects:
melanoma
braf
il-2
combination therapy
vemurafenib
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1423172

Internet

http://dx.doi.org/10.1080/2162402X.2017.1423172

Similar Items